DuPont/HEM Ampligen
Executive Summary
Phase III study in ARC patients terminated due to insufficient evidence of the drug's effectiveness in combating the AIDS virus. In a Oct. 13 joint release, the companies attributed the cancellation to "an interim analysis of the AMP 101 data [which] has failed to show any difference between Ampligen and placebo that would justify continuation of the study." The AMP 101 placebo controlled trial involved 330 patients with ARC at 11 medical centers nationwide. DuPont earlier dissolved the joint venture with the Philadelphia, Penn.-based HEM but agreed to continue supplying the anti-AIDS drug for the study ("The Pink Sheet" Aug. 22, T&G-1).